Clarifies on News Item
The Exchange had sought clarification from the company with respect to news article appearing in DNA on January 04, 2016 titled "Roche, Glenmark settle dispute over cancer drug".The company replied stating "Glenmark confirms that it has reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine - Erlotinib Hydrochloride. As part of the agreement, the companies have ceased all relevant patent... Clarification sought from Glenmark Pharmaceuticals Ltd
The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing in DNA on January 4, 2016 titled "Roche, Glenmark settle dispute over cancer drug." The reply is awaited. Roche, Glenmark settle patent dispute on Tarceva
Glenmark to acknowledge IPR of Roche, while the Swiss firm has agreed to give up costs and damages from Glenmark Glenmark seeks shareholders nod to raise $500 mn
Glenmark Pharmaceuticals has sought shareholders approval to raise up to $500 million (around Rs 3,300 crore) by issue of securities to fund its expansion plans, including setting up of new manuf... Newspaper advertisement for postal ballot process
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of the Advertisement published in the Newspapers regarding postal ballot process. Notice of Postal Ballot
Glenmark Pharmaceuticals Ltd has submitted to BSE a Copy of the Notice of Postal Ballot. Glenmark Pharmaceuticals receives ANDA approval for Linezolid Tablets, 600 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated December 22, 2015 titled "Glenmark Pharmaceuticals receives ANDA approval for Linezolid Tablets, 600 mg".
Glenmark settles patent war over Savella
Glenmark will have the option to market and distribute its Milnacipran Hydrochloride tablets or an authorized generic version of Savella tablets Glenmark Pharmaceuticals announces the settlement of Paragraph IV litigation with Forest Laboratories
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated December 21, 2015 titled "Glenmark Pharmaceuticals announces the settlement of Paragraph IV litigation with Forest Laboratories". Outcome of Operations Committee Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Operations Committee of the Board of Directors of the Company, at its Meeting held on December 15, 2015 allotted 2,000 equity shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.